Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Zhen Su, MD, MBA, to its Board of Directors, effective August 31, 2023. Dr. Su is currently Chief Executive Officer and a member of the Board of Directors at Marengo Therapeutics, Inc., a company pioneering novel T-cell targeting therapeutics to fight cancer.
“Dr. Su is a physician‐scientist and pharmaceutical industry leader who brings tremendous experience guiding products through discovery, clinical development, approval, and global commercialization,” said Richard Paulson, MBA, Chief Executive Officer of Karyopharm. “His expertise and counsel will be critical to us as we expand into different patient populations and potential new indications in oncology. We are delighted to welcome him to our team and look forward to the insight he will provide as part of our Board of Directors.”
“I am pleased to join the Board of Karyopharm at this exciting time in the company’s next phase of growth,” said Dr. Su. “I look forward to actively engaging with my fellow Board members and the Karyopharm leadership team to advance its core programs and deliver for patients in need of new cancer treatment options.”
“Dr. Su is a passionate leader focused on delivering medicines through all phases of the clinical development lifecycle,” said Barry Greene, Lead Independent Director of the Karyopharm Board. “We are thrilled to welcome such a strong strategic advisor and industry leader to our Board of Directors.”
Prior to joining Marengo, Dr. Su served as SVP, Global Head of Oncology Business Franchise, including US Head of the Oncology Business Unit, at Merck KGaA. Prior to that, he served as Chief Medical Officer at EMD Serono and headed leadership functions at Sanofi’s Oncology Division and GlaxoSmithKline. Before his industry career, Dr. Su served on the faculty of Duke University Medical School where he led early oncology clinical studies focusing on mRNA-based and cell-based immunotherapy and then at the University of Florida where he was the director of the Cell and Gene Therapy program. He received his Doctor of Medicine from Technical University of Dresden in Germany and his MBA from the University of Toronto in Canada.
About XPOVIO® (selinexor)
XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm’s Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved in the U.S. and marketed by Karyopharm in multiple oncology indications, including: (i) in combination with Velcade® (bortezomib) and dexamethasone (XVd) in patients with multiple myeloma after at least one prior therapy; (ii) in combination with dexamethasone in patients with heavily pre-treated multiple myeloma; and (iii) in patients with diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. XPOVIO (also known as NEXPOVIO® in certain countries) has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including but not limited to the European Union, the United Kingdom, China, South Korea, Canada, Israel and Taiwan. XPOVIO and NEXPOVIO is marketed by Karyopharm’s partners, Antengene, Menarini, Neopharm and FORUS, in China, South Korea, Singapore, Australia, Hong Kong, Germany, Austria, Israel and Canada.
Please refer to the local Prescribing Information for full details.
Selinexor is also being investigated in several other mid- and late-stage clinical trials across multiple high unmet need cancer indications, including in endometrial cancer and myelofibrosis.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been an industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm’s lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic neoplasms and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.
